Cannformatics Announces Scientific Reports Publication Revealing Groundbreaking Progress in Personalizing Medical Cannabis Treatment for Autism Spectrum Disorder
SAN FRANCISCO, Aug. 24, 2023 /PRNewswire/ -- Cannformatics an early-stage biotechnology company announced today that its paper titled, "A Machine Learning Approach for Understanding the Metabolomics Response of Children with Autism Spectrum Disorder to Medical Cannabis Treatment" was published by Nature's Scientific Reports. This paper unveils the company's progress towards launching a saliva-based lab testing service to guide healthcare providers, patients, and families with personalized medical cannabis treatments. The initial service is expected to launch for people with ASD within six-months of the company completing its Series-A fundraising round.
- This approach opens new opportunities for developing patient-specific therapies that can go beyond the use of medical cannabis.
- SAN FRANCISCO, Aug. 24, 2023 /PRNewswire/ -- Cannformatics an early-stage biotechnology company announced today that its paper titled, "A Machine Learning Approach for Understanding the Metabolomics Response of Children with Autism Spectrum Disorder to Medical Cannabis Treatment" was published by Nature's Scientific Reports .
- This paper unveils the company's progress towards launching a saliva-based lab testing service to guide healthcare providers, patients, and families with personalized medical cannabis treatments.
- "For years, the cannabis industry has searched for scientifically valid published data that showcases the medical benefits and safety of cannabis.